Teladoc Health's stock has faced significant declines, hitting a record low of $8.10 after a disappointing second quarter where revenue dropped 2% to $642.4 million. The company's BetterHelp segment, which saw a 9% revenue decline, has been a major factor in its financial struggles, resulting in a substantial $790 million impairment charge. As a response to these challenges, Teladoc has withdrawn its financial outlook for 2024 and is undergoing a strategic reevaluation under new CEO Chuck Divita, who emphasizes the need for improved operational performance. Several analysts, including Deutsche Bank and Barclays, have reduced their price targets for Teladoc, with consensus ratings remaining at 'Hold'. Despite some growth in the Integrated Care segment, the overall outlook remains uncertain, prompting discussions of potential restructuring or a sale of the BetterHelp unit. The company has suffered a cumulative decline of 60% in stock value throughout 2024, marking a troubling trend for the provider.